LENSAR Reports Second Quarter 2025 Results and Provides Business Update

LENSAR Reports Second Quarter 2025 Results and Provides Business Update GlobeNewswire August 07, 2025 18 ALLY Robotic Cataract Laser Systems(TM) (“ALLY Systems”) placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 […]

GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates

GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire August 07, 2025 Global pivotal program initiation on track for 2026 Engagement with FDA on GH001 IND complete response ongoing The fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychotherapy Treatment

HUTCHMED Reports 2025 Interim Results

HUTCHMED Reports 2025 Interim Results GlobeNewswire August 07, 2025 — Indications expansion driving growth and ATTC platform enriching pipeline — — $455 million in net income attributable to HUTCHMED driven by non-core partial disposal — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED“, the “Company”

Tower Semiconductor to Participate in August and September Investor Conferences

Tower Semiconductor to Participate in August and September Investor Conferences GlobeNewswire August 07, 2025 MIGDAL HAEMEK, Israel, August 7, 2025 – Tower Semiconductor (NASDAQ/TASE: TSEM), the leading foundry of high value analog semiconductor solutions, today announced that its company representatives will participate in the Needham 6th Annual Virtual Semiconductor and SemiCap 1×1 Conference on Wednesday,

Upwork Reports Second Quarter 2025 Financial Results

Upwork Reports Second Quarter 2025 Financial Results GlobeNewswire August 07, 2025 Achieves record second quarter with revenue of $194.9 millionGenerates GAAP net income of $32.7 million and adjusted EBITDA of $57.1 million, resulting in 17% profit margin and 29% adjusted EBITDA marginRaises FY2025 revenue and adjusted EBITDA guidanceAcquires Bubty and agrees to acquire Ascen to

Verano Announces Second Quarter 2025 Financial Results

Verano Announces Second Quarter 2025 Financial Results GlobeNewswire August 07, 2025 CHICAGO, Aug. 07, 2025 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced its financial results for the second quarter ended June 30, 2025, which were prepared in accordance with U.S.

Tecnoglass Reports Record Second Quarter 2025 Results

Tecnoglass Reports Record Second Quarter 2025 Results GlobeNewswire August 07, 2025 – Record Quarterly Revenue of $255.5 Million, Up 16.3% Year-Over-Year with Double Digit Organic Growth in Both Single-Family Residential and Multi-Family/Commercial Businesses –– Single-Family Residential Revenue Achieved a Second Quarter Record of $109.6 Million, Up 14.5% Year-Over-Year –– Single-Family Residential Orders Grew 29.0% Sequentially,

Xali Gold Trading Halt

Xali Gold Trading Halt GlobeNewswire August 07, 2025 VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) — Xali Gold Corp. (TSXV: XGC) (“Xali Gold” or “the Company”) advises that the British Columbia Securities Commission has notified the Company that it has issued a cease trade order (“FFCTO”) under Multilateral Instrument 11-103 – Failure-to-File Cease Trade

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings GlobeNewswire August 07, 2025 Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential Transaction expected to be near-term accretive to EPS

XORTX Provides Corporate Update and Planned Activities for 2025 / 2026

XORTX Provides Corporate Update and Planned Activities for 2025 / 2026 GlobeNewswire August 07, 2025 CALGARY, Alberta, Aug. 07, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company“) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney

Scroll to Top